Is Merck KGaA (MilliporeSigma) profitable in 2026?

Yes. Merck KGaA posted 2025 group net income of 2.608 billion euros (down 6.1% YoY, EPS 6.00 euros) per its 2026-03-05 annual report, and beat Q1 2026 estimates with EPS of 2.11 euros versus 1.99 forecast, reported 2026-05-13.

Could AI replace MilliporeSigma's business?

Unlikely in the near term. MilliporeSigma's core is GMP-regulated manufacturing of validated bioprocessing consumables and reagents across a 300,000-SKU catalog (per 2026-07-24 wiki data), a physical/regulatory moat that language models cannot manufacture. AI mainly threatens peripheral catalog lookup and ordering functions, not certified production.

Who is MilliporeSigma's biggest competitor?

Thermo Fisher Scientific is described as the life-science-tools market leader with roughly 15-24% share depending on segment definition, per a 2026-01-06 Mordor Intelligence analysis, and is pursuing the Solventum filtration/purification acquisition that overlaps MilliporeSigma's bioprocessing stronghold.

Is Merck KGaA getting acquired or acquiring companies in 2026?

Merck KGaA is the acquirer: it signed an agreement on 2026-06-24 to buy Bio-Techne Corporation for $73 per share in cash, an enterprise value of about $11.3 billion, expected to close late 2026 or early 2027 pending regulatory approval.

Why did Merck KGaA's stock drop in early 2026?

Merck KGaA shares fell more than 10% after a Q4 2025 earnings miss, with EPS of 1.88 euros versus a 1.96 euro forecast, even though full-year guidance was technically met, according to a 2026-03-27 Investing.com report.

What is driving Merck KGaA's Life Science segment growth in 2026?

Life Science organic sales grew 8% in Q1 2026, with the Process Solutions unit up 16% and surpassing 1 billion euros in quarterly revenue for the first time since Q1 2023, per a 2026-05-13 earnings call transcript.

Biotech tools companies · Germany

Merck KGaA (MilliporeSigma)

merckgroup.com ↗

German conglomerate selling lab reagents and filters (MilliporeSigma), plus pharma and chip materials.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from late 2026 or early 2027 · Every call on the record Checkpoint: Bio-Techne acquisition expected to close

The call

MilliporeSigma sells regulated consumables that no chatbot can manufacture, while Thermo Fisher circles the same shelf space and AI-lab platforms build around it without it.

Merck KGaA's MilliporeSigma division makes filters, reagents, and lab equipment that biotech and pharma companies need to follow strict government rules when making drugs. It is hard to copy because customers have to re-test and re-approve any new supplier, which takes years and costs money, so they stick with what works. The main threats are that Thermo Fisher (the larger competitor) is buying Solventum to get into the same business, money spent on lab tools could drop if research budgets shrink, and Merck is not yet part of new AI-powered lab automation systems that could eventually change how labs work. None of these would sink the company in the next three to five years, but they are worth watching.

Why

AI pressure: NVIDIA BioNeMo Agent Toolkit and partner lab-automation ecosystem. NVIDIA's new agentic lab platform lists Benchling, Certara, Databricks as partners; MilliporeSigma is not named among them. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific. Thermo Fisher's pending Solventum filtration and purification deal overlaps directly with MilliporeSigma's bioprocessing consumables business. Could a giant copy it? No, they are blocked.

What protects it. Bioprocessing consumables are GMP-validated; swapping suppliers means re-validating drug manufacturing lines, which customers avoid.

What would change this call

Thermo Fisher's Solventum filtration/purification deal closes and reports organic growth in overlapping product lines. Would show Thermo Fisher converting the acquisition into actual share gains against MilliporeSigma.
Merck KGaA's Bio-Techne deal closes on schedule (late 2026/early 2027) within the ~€500m integration budget. Would show the company defending its bioprocessing position rather than losing ground during integration.
MilliporeSigma announces a partnership or product tie-in with NVIDIA BioNeMo, Benchling, or similar agentic lab-automation platforms. Would show the company closing its current absence from AI-native lab workflow ecosystems.

Key numbers

Life Science segment sales: 8,980m euros, +4.0% organic (2025 (reported 2026-03-05))
Bio-Techne deal: 73 dollars/share, ~11.3B enterprise value (2026-06-24)
Group net income: 2.608bn euros, down 6.1% YoY (2025 (reported 2026-03-05))

Named risks

Bio-Techne integration costs estimated at ~500 million euros could overrun before late 2026/early 2027 close. Severity: medium
Mavenclad full US generic erosion as of May 2026 continues to drag Healthcare organic sales. Severity: medium
Strategic absence from NVIDIA BioNeMo and MGI Tech agentic lab-automation ecosystems as of mid-2026. Severity: medium
Soft China and US academic/government spending weighing on Life Science catalog reagent sales. Severity: medium
US pharmaceutical tariffs effective July/September 2026 could raise input costs depending on MFN/onshoring deal terms. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	Pending Solventum filtration/purification acquisition overlaps MilliporeSigma stronghold, ~15-24% market share as of 2026-01-06
Danaher	contesting	Bioprocessing workflow rival coexisting in oligopoly, no reported organic share loss as of 2026
Sartorius AG	contesting	Competes in bioreactors and single-use assemblies, partnered with Lonza on cell/gene therapy manufacturing
NVIDIA BioNeMo ecosystem (Benchling, Certara, Databricks, Snowflake, Seqera)	losing to	MilliporeSigma not named as partner in June 22, 2026 BioNeMo Agent Toolkit launch
MGI Tech / Shanghai AI Lab	losing to	Launched Physical AI lab automation tools ProtoPilot and BioLab Bench in July 2026, MilliporeSigma absent

Questions people ask

Is Merck KGaA (MilliporeSigma) profitable in 2026?: Yes. Merck KGaA posted 2025 group net income of 2.608 billion euros (down 6.1% YoY, EPS 6.00 euros) per its 2026-03-05 annual report, and beat Q1 2026 estimates with EPS of 2.11 euros versus 1.99 forecast, reported 2026-05-13.
Could AI replace MilliporeSigma's business?: Unlikely in the near term. MilliporeSigma's core is GMP-regulated manufacturing of validated bioprocessing consumables and reagents across a 300,000-SKU catalog (per 2026-07-24 wiki data), a physical/regulatory moat that language models cannot manufacture. AI mainly threatens peripheral catalog lookup and ordering functions, not certified production.
Who is MilliporeSigma's biggest competitor?: Thermo Fisher Scientific is described as the life-science-tools market leader with roughly 15-24% share depending on segment definition, per a 2026-01-06 Mordor Intelligence analysis, and is pursuing the Solventum filtration/purification acquisition that overlaps MilliporeSigma's bioprocessing stronghold.
Is Merck KGaA getting acquired or acquiring companies in 2026?: Merck KGaA is the acquirer: it signed an agreement on 2026-06-24 to buy Bio-Techne Corporation for $73 per share in cash, an enterprise value of about $11.3 billion, expected to close late 2026 or early 2027 pending regulatory approval.
Why did Merck KGaA's stock drop in early 2026?: Merck KGaA shares fell more than 10% after a Q4 2025 earnings miss, with EPS of 1.88 euros versus a 1.96 euro forecast, even though full-year guidance was technically met, according to a 2026-03-27 Investing.com report.
What is driving Merck KGaA's Life Science segment growth in 2026?: Life Science organic sales grew 8% in Q1 2026, with the Process Solutions unit up 16% and surpassing 1 billion euros in quarterly revenue for the first time since Q1 2023, per a 2026-05-13 earnings call transcript.

Timeline

2026-07-05MGI Tech and Shanghai AI Lab unveil ProtoPilot and BioLab Bench Physical AI lab automation tools
2026-06-25Merck KGaA announces agreement to acquire Bio-Techne for about $11.3 billion
2026-06-22NVIDIA launches BioNeMo Agent Toolkit for agentic life-science workflows without MilliporeSigma as named partner
2026-05-21MilliporeSigma launches Supplier Sustainability Toolkits
2026-05-13Q1 2026 results: EPS 2.11 euros beats forecast, Life Science organic growth of 8%
2026-03-27Q4 2025 earnings miss sparks stock selloff of over 10%
2026-03-05Merck KGaA publishes 2025 Annual Report showing group net sales of 21.1 billion euros
2026-02-24Verified Market Research profiles Merck KGaA among top life science product companies
2024-08MilliporeSigma closes acquisition of Mirus Bio for viral vector bioprocessing
2023-12-05MilliporeSigma launches AIDDISON generative AI drug discovery platform

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Intertek Group plc Eurofins Scientific SE Carl Zeiss AG